Mykofenolat Accord (Mycophenolate Mofetil)

• Mycophenolate Mofetil is used as an antimetabolite immunosuppressant to inhibit lymphocyte proliferation in specific clinical settings.
• Organ transplant rejection: helps prevent rejection of transplanted organs such as kidney, liver or heart.
• Lupus nephritis: reduces disease activity and proteinuria in patients with systemic lupus erythematosus affecting the kidneys.
• Bone marrow transplantation: used as part of graft‑versus‑host disease prophylaxis to lower the incidence of GVHD.

• Mycophenolate Mofetil selectively inhibits inosine monophosphate dehydrogenase, a key enzyme in the de novo synthesis of guanosine nucleotides. By depleting guanosine pools, the drug suppresses proliferation of T and B lymphocytes, which rely heavily on this pathway, thereby reducing immune activation and graft rejection.

Common Side Effects

• Nausea or vomiting
• Diarrhea or abdominal discomfort
• Headache
• Upper respiratory tract infections
• Elevated liver enzymes

Serious or Rare Side Effects

• Leukopenia or neutropenia leading to increased infection risk
• Severe opportunistic infections (e.g., CMV, PCP)
• Malignancies such as lymphomas or skin cancers
• Hepatotoxicity with jaundice or hepatitis
• Teratogenic effects (Category X) causing fetal malformations

Mycophenolate Mofetil requires careful monitoring and patient counseling to minimize risks.

• Blood counts: monitor complete blood count regularly to detect leukopenia.
• Liver function: assess hepatic enzymes periodically for signs of toxicity.
• Infection risk: avoid live vaccines and promptly treat any signs of infection.
• Pregnancy: contraindicated in pregnancy; ensure effective contraception for women of childbearing potential.
• Renal impairment: adjust dose or monitor drug levels in patients with reduced kidney function.
• Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Mycophenolate Mofetil can interact with several drug classes, requiring dose adjustments or monitoring.

Major Interactions (Avoid)

• Azathioprine: additive myelosuppression may lead to severe bone‑marrow toxicity.
• Cholesterol‑binding resins (e.g., cholestyramine): can reduce mycophenolate absorption.
• Antacids containing aluminum or magnesium: may decrease bioavailability.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase mycophenolate plasma concentrations.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): decrease drug exposure, risking loss of efficacy.
• Warfarin: may enhance anticoagulant effect; monitor INR closely.
• Vaccines: live attenuated vaccines may cause infection; assess risk versus benefit.